Noninfectious Pulmonary Complications: Diffuse Alveolar Hemorrhage - - PDF document

• !

Noninfectious Pulmonary Complications:

Diffuse Alveolar Hemorrhage and Bronchiolitis Obliterans Syndrome

" # $ % %& &$ &'( " '%(%(&%&&$ (&'( )" '%(%(&* *%&'( Objectives

• + $%

+ , %

• ./01
• %'(& *%%
• $&1&%

+ &%& $/& $ + %& $$ 2%( &/& $$ %&& $ Overview of all Pulmonary Complications

)

• Timeline of Pulmonary Complicatons
• From Soubani and Pandya (2010) Hematol Oncol Stem Cell Ther

Prognostic

+ 33%&456#.

• 78 %

%/ % + # %/9:5 ;<=1% %> + $ %' (& '

6;>??

Not Prognostic

• 4%)/456#
• * $
• (@
• .
• !%%
• 5( $
• #$
• /#A
• ?,

Pulmonary Complications – Prognostic Factors For Early Severe

Pulmonary Complications (< Day +100)

• Pulmonary Complications – Conventional Allo SCT vs

Nonmyeloablative SCT

,%&& *'* % B + %&& $/%

• + ,* ($C
• %'%' % &%/

%

• 6( % && $$%?
• #* ";>??

• )

Independent risk factors associated with pulmonary complications + # %#A + ,% &

& ;>

Factors associated with mortality + . + 6&$% + #$ + # %95 + D& + !%(%(

Pulmonary Complications – Risk Factors – Auto SCT

E

#&&$6( ;#6>

+ )=%(%'/AA%#A?6A ) + %%)&*'?, %( + 456#.'8 + ,#.(#/'&$ F2 2 % &. + $ %*&*$% $ + #G'(&?'' H$"6%&*%$$ ' $((" Case Giovanni “Gio”

I

• + % (&.2$*&2%

(*%?A&$% + % % *&/1' $%% % *1 + #%$ ( 0/1 + $$H$,! % + #$$%$$/(&$2#2&

• DAH
• + -

+ &

• (@
• ?,
• &%$
• &C

+ (& + $ + $ + $&& + $456# + # + 4'&

DAH – Risk Factors DAH + ($ - *%( **(%$( %($( &&% + ! && $& %( %$(J$ $& + .J& % &%&&$%( + , % & %' $ - H$/ %$&$. $J$

• DAH Pathogenesis

)

Nadir and Brenner (2012) Blood Reviews

DAH Presentation

+ & $'/(&

• %&)%

+

• #
• %$ $(
• 9
• #&&$$&
• 33

DAH Diagnosis

+ %(&%(

• #&&$2($%( (

% '*

+ %( &%($)% %( + #(*?A

• DAH – Diagnostic Criteria

" :% &'%%J$&%* $*$&2(%& $2%*(''%%/ (% " ?A'((*%$&) $*(* 1%/ % (.&?A&$%",& $( *&%2@)1$& & .%$($ %**% )" * && *'%(

& ;> %

+ .*'#6%,6 + *%&& $ %($*'' + $(( % + $&%(#6%,6* '0/% + ' (/%% && ',6 + $%#6 $%,6 Is it DAH or InfectionAssociated Hemorrhage (IAH)?

E

+ '&II (' #6%,6(' + '#6%E',6 + %(*%.)%(*%.) % (*%.)% 0(*%.)% 0( %$%&&% + $ C

• %(2 %$ 2* %(2

456# %%% & %&6

• **&0%$01#6%)1,6
• *$%'(%%
• (%%0%$&01 %

1'$%

J ;0>??

Comparing DAH and IAH

=

• E

+ $%* + 6(/%%* + %%(( '% + %%&&* (* %'' + $%& / %(

• DAH Management

I

Supportive Care + .( + + ?%%$ %

• ?%
• 99

Therapies + % + %- * %(&* + 95,, - *$ & /%%' &%J$% $& /%% % ( & ,8%8 $& & %

DAH Management

• +

6(%%& + &"K%;II>

• )($

+ $ + A'%%;<)(> + 6(%%;@)(>

+ "?;III>

• E (&( - '#6
• %(/"4%.%''

+ A'"?;>

• ) &#6'( (
• %(/ 4%

+ "&,%;II>

• ($&
• 4%.)%&'%*)%

DAH Management – Steroid Dosing

• =

+ L"??;0>

• '#6%'%;/4%>"

$*($&=%' %(,5H0"

• %G %($

+ 1/%#6

• %/($

+ =)1/%

DAH Management – Aminocaproic Acid

• +

'I%$%&#6 + $*%%%';<(%>2%$;/(%>% (/%;@(%>%($''$ + *J ')202%%,!% + %'=1 + 35% of this population had positive respiratory cultures + $ C

• ,%G($'(& %&&

)202%

• ,%/($'%%%',!%
• ,$- %$%(/%%'

%'(,! %'/%($

Low, Medium, and highdose steroids with or without aminocaproic acid in adult hematopoietic SCT patients with diffuse alveolar hemorrhage Rathi et al. (2014) BMT

)

+ ' + H$%,! %EH$%$* + %)/ ((95,, H$ % J$%(%%H$"%% *%(' G/ )( + =%% + #'%$$/(&$22%( $%(% + %* '*% + $/ && (%% $%( %

";>K %

DAH– Activated Factor VII

• I

+ 6 + ?A0

• M %*%%

$($'2 $("?A& A%*%$N

+ ($$0

• M(&( "

(2* 2?% %$N

• (&$ %

&$(

• $$(

DAH – Back to the Case

• DAH – Back to the Case – second CT 4/24/14

? *% ;?>

E

• + )&%(%'A%!#=E

+ $ %* 456#%$ $& + %''(?"9%( $ ;6> '? + %'(/%%'

• BOS Patient Case

=

+ #&%$ & F% *&'*$ %( F%* (&*%*&* %(& 456# + /& $$ &'(( + , % - )1'&E1/I1 + (& && OA + &? %'(& *% BOS Definition/Description

I

+ %(&% + 4%(&6A + ?, + &4:# + # %((*$ + ?$$&/*% %( ( + 456#. + !%(( % + * $ + $456# +

• +

, %$&? + #&5 &$F$& ' &%&

?";>:K

+ &9/;9:595

<"E>

+ **Association between development of alliterative bronchiolitis and the presence of active cGVHD + *(' ( 456#H$ 456#% 456#

BOS – Risk Factors

)

• + A

+ !$&% + =1& *'0% + $$%$ +

• # $(;0/1>2%;/E1>
• LF(
• 9$ %'& $
• P1 %%($ %*%9

+ $

• 5*
• ''(&'*$ ;9>'

%&. *&9

BOS Presentation

)

+ ** $ ' %/ ( &* %(& + (/ .

• $&$(J$ %* %((
• $&& $(
• $

BOS Pathogenesis

)

BOS – Pathogenesis Barker et al. (2014) NEJM

))

• +

+ $&$ (;9> + ((

• & $/& $(
• 82'J/& $

%%H$6

+ #( %$

• & $/& $(
• ?A
• A$(*

BOS Diagnosis + 9$&) (

• A$($
• #&&$

+ $%$%%(%&' ?")$C

• 95- & %
• 9:5- & %.$ %
• 9:595- %&*$

+ #( &?C

• :% &&'*$ '9:595<"E%9:5<E1

% %"

• BOS PFTs

)

+ SPIROMETRY :

:/8/8 Parameter !%?1%?1%1( 95A)"=E"I)"E0 FEV1 Liters 3.07 1.07 35 1.17 38 9 FEV1/FVC % 79 55 54 2

RESULTS: 10/14/14 + 9529:52%9:595%$ %" (& * % %"%&&$( % %" 5 %" IMPRESSIONS: + '*$ "(& * % %"% % %&&$( $((& *% %&&$* "%5$(((" $%&E))95%9:5 % %"#A$ (%" + ,#I#,4,C + "* $(% ;0")>

Our Patient’s Most Recent PFTs

)0

• )

+ .

• :(- *
• A(- (&&&'%** '

%%% %* %& (

+ 6($ ;6>/ % %$&

• 9%(- (2* ' (2* 2%

* %

• & $ $

+ ? - % + * *- %% + $( $(**5- &( & H$% BOS Diagnosis

)E

HRCT 4/2008

)=

+ 6

• =/

+ 6%(' ?

• ,:,C

+ 9%(&* * ' * ( *

HRCT 4/2010

)I

• BOS – Diagnostic Criteria

Suggested Criteria "( " 456# )":% &&'*$ '9:595<"E%9:5<E1 % %"

• "(' (* 6&

'%. $2%$$&9 @1 % % "* && *% 2%(2 *( $$2$$ $$?A 0"( && * ;*H$%& %(&* >

";)> J"2;>??

• + (%&& $%%$

$(&$ + (&*F + C

• %

+ %"((%&/0'",& % ( *F/ ')

• ,$$(

+ $ *

+ %%&)/ BOS Treatment

• +
• F$ - %*%
• AF - (H/L%/9
• M$- (%

+ ?%%$($ $((9/&%&* && + ;?>C

• '0
• ='? % %
• 0%.$9/%=I(;/)0(>

%E0)(;0/E=I> ($

• 9:5 (9($'1 %1 ($
• $((9($*% *% %'

%

BOS – Treatment FAM

• + 6*%&& &$(

%*? + A$ %";>?

• I- %&'/$&)
• %''&)/'

%% %%/)/''(( H/'&H$

• %$*&%$($%';(/E>% $%%

$$%9

• 0&I%%:&%&%;(/I=

%>

• %&% 2% %

%% %9

BOS – Treatment – Extracorporeal Photophoresis

)

+ A%%C

• 9'$(/9 *%$

&.*

• ,*
• $.*
• ,$$(*$

BOS – Other Strategies

• + ,& .
• (J 2&$($2%5(
• (&$F%$ $
• &$&

+ A(/ + $*

• &C

+ :. ( + $ $( + :%$ $(% %%'( + :(/ ( H$ + ?(( + ( $(%($$

• ";>??- %(&

&$ ( 2%0/$'% 2$*J &%2%.

BOS – Supportive Treatment and Management of Advanced Cases

• + %$(
• .
• (";>??

+ ($'%/($ + & %'(%(/$ C$( (2/&&2% &%/ (%&$ && 456#H$ '$$

BOS – Supportive Treatment and Management of Advanced Cases

" $ *6Q.&$ %%&022%& " . %%&H$ $%(9' 456# )" 6&($%*%%' &($%* $%(%(( " ,'(&$( 29%& $% %( $%*&% % %"9! $$%*($%%* $ &' (F%%&

ASBMT Guidelines “Recommended Screening and Preventative Practices for LongTerm Survivors after Hematopoietic Cell Transplantation” Majhail et al. (2012) BBMT

E

+ (%%(*9 + # $$'" %(?%( &$ + :. * * %''( &$(&$ + (($=/1&

• + *F%&$%9:5

+

• I1)
• 1
• =1

BOS Outcomes

=

• E

+ 9 %' %C

• %%&9:5- 1$
• (@0
• ( 456#
• !%(%
• 6&&
• 9$%(

+ 9 %'(C

• &9
• $ &
• #(& (
• 5( $
• &456#.

BOS Outcomes

I

+ ?R? *(F($' 'R( /(F($ + # % *%&'($% + #? + & *? + $$ $''&&2 %$ $(2%% Is it BOS or BOOP (now known as COP)?

• Features

BO COP

, % /=1 <1

• (

%$

• A;>

!$&%

• $(2%2'F

$(2%2& %( 9%( S&%2(2 * %2 ($%( 2%$ 9 *$ S#A S% %#A #( 2%( 2( $* 6( 9* $(*(* ' &% (S %%$ 4$$(&* 2 .%( S &%&*

• %%$$

% $ S( %'( 4%S *

Comparison Between BO and BOOP/COP

• $*";>6

• =

+ $%% + 6%%&& $(%' (%%H$%$'% + 6*$ &$ %$ $ + A&% $ Back to the CaseH

• Thank You for Your Attention

)